Kinetics and Patterns of PSMA PET Uptake in Prostate Cancer after Radiation Therapy: A Single Center Retrospective Study

Abstract

<h3>Purpose/Objective(s)</h3> The kinetics of PSMA PET uptake in prostate cancer lesions after radiation therapy (RT) is unknown. The aim of this study was to assess the patterns of PSMA PET uptake in irradiated lesions using serial PSMA PET/CT scans. <h3>Materials/Methods</h3> This was a single-center retrospective study that included patients with prostate cancer who underwent one PSMA PET/CT scan before RT and at least one other scan after RT between November 2016 and July 2021. One reader (M.H.) analyzed the target lesions uptake by visual criteria (uptake above background) and semi-quantitative analysis. Lesions with and without residual uptake were compared for 1) time-interval after RT, 2) lesion tissue type (prostate, prostate bed, lymph node, and bone), 3) RT type (stereotactic body RT, intensity-modulated RT, three-dimensional conformal RT, and proton therapy), 4) baseline uptake intensity (SUVmax), and 5) PSMA-derived tumor volume (PSMA-TV). Lesions with residual uptake were followed-up. Diagnosis of eventual progression was made by biopsy or subsequent follow-up imaging when available. <h3>Results</h3> A total of 108 patients with available clinical and imaging data on 257 irradiated lesions (lymph node: n = 126; bone: n = 98; prostate: n = 25; prostate bed: n = 8) were included. The median time from end of RT to follow-up PET was 10.6 (range: 0.4-51.7) months. Residual uptake after RT was observed in 90/257 (35.0%) of the irradiated lesions. The mean % decrease in SUVmax of the irradiated lesions on the follow-up PET performed at <3 (n = 20), 3-6 (n = 38), 6-9 (n = 58), and 9-12 (n = 27) months post-RT were 41.4%, 53.8%, 65.6%, and 69.7% (p = 0.004). Residual uptake was more commonly seen in the prostate (prostate 68.0%; bone 40.8%; prostate bed 25.0%; lymph node 24.8%, p < 0001), and associated with higher baseline uptake and lesion size: SUVmax 9.5 vs 6.4 (p < 0.001) and PSMA-TV 1.7 vs 1.0 ml (p = 0.002) in lesions with residual uptake vs. without, respectively. RT type was not associated with the residual uptake (p = 0.17). In multivariate logistic regression analysis, shorter time after RT (OR: 0.93 [95%CI: 0.89-0.97]), higher baseline SUVmax (OR: 1.07 [1.03-1.11]), and lesion in the prostate (OR: 6.84 [2.19-21.3]) were independently associated with residual uptake. Among the lesions with residual uptake, 28/90 (31.1%) lesions were subsequently evaluated by biopsy and/or follow-up imaging, and 6/28 (21.4%) lesions were eventually showed progression. Risk factors of recurrence were a residual uptake observed after a long time-interval from the end of RT (recurrence vs non-recurrence: 15.8 vs 3.7 months, p = 0.002) in the prostate lesion (prostate 50.0%; bone 12.5%; lymph node 0.0%, p = 0.044). When using a cutoff value of >8.6 months after RT, the presence of residual uptake was diagnostic of recurrence with a sensitivity of 0.83 and specificity of 0.86 (AUC: 0.92). <h3>Conclusion</h3> The PSMA PET uptake of irradiated lesion decreases gradually over one year, while the uptake in the prostate tends to remain longer than in bone and lymph node lesions.